France has agreed to provide temporary funding to help a clinical trial of an experimental therapy for glioblastoma, a notoriously hard-to-treat form of brain cancer, to go ahead.The French High Authority for Health (HAS) will take over the costs of providing Carthera’s SonoCloud-9 drug delivery device to French subjects in the pivotal SONOBIRD trial, which aims to enrol around 560 recurrent glioblastoma (rGBM) patients across 40 sites in the US and Europe over the next two years.
